Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13206685 | 0.89 | CCR2 (0.46) | CCR2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1757701 | 0.86 | RAB9A (0.46) | CCR2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL13206688 | 0.85 | RAB9A (0.60) | CCR2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL28815311 | 0.80 | KDM4E (0.57) | KDM4EGLAALDH1A1MAPK1STAT3 | |
| SCHEMBL27695738 | 0.79 | ALDH1A1 (0.44) | CCR2KDM4EGLAALDH1A1LMNA | |
| SCHEMBL2988492 | 0.77 | KDM4E (0.51) | CCR2KDM4EGLAALDH1A1MAPK1 | |
| SCHEMBL28776219 | 0.76 | PTGDR2 (0.41) | CCR2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL27648030 | 0.76 | PTGDR2 (0.45) | KDM4E | |
| SCHEMBL1194101 | 0.76 | THRA (0.49) | KDM4EGLAALDH1A1MAPK1STAT3 | |
| SCHEMBL13224503 | 0.75 | KDM4E (0.49) | KDM4EGLAALDH1A1MAPK1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781598-B2 | Process for the preparation of substituted indoles | ASTRAZENECA AB (SE) | 2010-08-24 | — | — | US | disclosed |
| US-7781598-B2 | Process for the preparation of substituted indoles | ASTRAZENECA AB (SE) | 2010-08-24 | — | — | US | disclosed |
| US-7781598-B2 | Process for the preparation of substituted indoles | ASTRAZENECA AB (SE) | 2010-08-24 | — | — | US | disclosed |
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| EP-1844012-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006075139-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | IDO1, IDO2, TPH1 | CCR2 1316/4885KDM4E 565/4885GLA 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.